ADTX

Company Overview — What Does Aditxt, Inc. Do?

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia. Aditxt, Inc. (ADTX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Amro Albanna and employs approximately 60 people. With a market capitalization of $466,019, ADTX is one of the notable companies in the Healthcare sector.

Aditxt, Inc. (ADTX) Stock Rating — Avoid (April 2026)

As of April 2026, Aditxt, Inc. receives a Avoid rating with a composite score of 13.8/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.ADTX ranks #4,419 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Aditxt, Inc. ranks #833 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ADTX Stock Price and 52-Week Range

Aditxt, Inc. (ADTX) currently trades at $0.50. The stock lost $0.03 (5.4%) in the most recent trading session. The 52-week high for ADTX is $12.92, which means the stock is currently trading -96.1% from its annual peak. The 52-week low is $0.05, putting the stock 923.5% above its annual trough. Recent trading volume was 434K shares, suggesting relatively thin trading activity.

Is ADTX Overvalued or Undervalued? — Valuation Analysis

Aditxt, Inc. (ADTX) carries a value factor score of 6/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.07x, versus the sector average of 2.75x. The price-to-sales ratio is 27.95x, compared to 1.66x for the average Healthcare stock.

At current multiples, Aditxt, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Aditxt, Inc. Profitability — ROE, Margins, and Quality Score

Aditxt, Inc. (ADTX) earns a quality factor score of 5/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -1126.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -269.6% versus the sector average of -33.1%.

On a margin basis, Aditxt, Inc. reports gross margins of -1672.9%, compared to 71.5% for the sector. The operating margin is -413035.6% (sector: -66.1%). Net profit margin stands at -1164875.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -98.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ADTX Debt, Balance Sheet, and Financial Health

Aditxt, Inc. has a debt-to-equity ratio of 318.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 0.31x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $5M. Cash and equivalents stand at $163,041.

ADTX has a beta of 45.96, meaning it is more volatile than the broader market — a $10,000 investment in ADTX would be expected to move 4496.0% more than the S&P 500 on any given day. The stability factor score for Aditxt, Inc. is 1/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Aditxt, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Aditxt, Inc. reported revenue of $9,624 and earnings per share (EPS) of $-1153.83. Net income for the quarter was $-45M. Gross margin was -1672.9%. Operating income came in at $-20M.

In FY 2025, Aditxt, Inc. reported revenue of $3,195 and earnings per share (EPS) of $-1153.83. Net income for the quarter was $-43M. Gross margin was 8.4%. Revenue grew -97.6% year-over-year compared to FY 2024. Operating income came in at $-20M.

In Q3 2025, Aditxt, Inc. reported revenue of $748 and earnings per share (EPS) of $-548.78. Net income for the quarter was $-24M. Gross margin was 2.1%. Revenue grew -89.1% year-over-year compared to Q3 2024. Operating income came in at $-3M.

In Q2 2025, Aditxt, Inc. reported revenue of $1,004 and earnings per share (EPS) of $-3.45. Net income for the quarter was $-7M. Gross margin was -0.1%. Revenue grew -97.7% year-over-year compared to Q2 2024. Operating income came in at $-6M.

Over the past 8 quarters, Aditxt, Inc. has experienced revenue contraction from $44,276 to $9,624. Investors analyzing ADTX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ADTX Dividend Yield and Income Analysis

Aditxt, Inc. (ADTX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ADTX Momentum and Technical Analysis Profile

Aditxt, Inc. (ADTX) has a momentum factor score of 17/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 30/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ADTX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Aditxt, Inc. (ADTX) ranks #833 out of 838 stocks based on the Blank Capital composite score. This places ADTX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ADTX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ADTX vs S&P 500 (SPY) comparison to assess how Aditxt, Inc. stacks up against the broader market across all factor dimensions.

ADTX Next Earnings Date

No upcoming earnings date has been announced for Aditxt, Inc. (ADTX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ADTX? — Investment Thesis Summary

The quantitative profile for Aditxt, Inc. suggests caution. The quality score of 5/100 flags below-average profitability. The value score of 6/100 indicates premium valuation. Momentum is weak at 17/100, a headwind for near-term performance. High volatility (stability score 1/100) increases portfolio risk.

In summary, Aditxt, Inc. (ADTX) earns a Avoid rating with a composite score of 13.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ADTX stock.

Related Resources for ADTX Investors

Explore more research and tools: ADTX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ADTX head-to-head with peers: ADTX vs AZN, ADTX vs SLGL, ADTX vs VMD.